CD8A and neoplasm: Through targeted T cell depletion experiments, we established that CD8<sup>+</sup> T cells are indispensable for the vaccine's anti-tumor activity, whereas CD4<sup>+</sup> T cell depletion had no significant impact on therapeutic outcomes.